摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(1-benzyl-4,5,6,7-tetrahydro-1H-indol-2-yl)aniline | 1450893-00-1

中文名称
——
中文别名
——
英文名称
4-(1-benzyl-4,5,6,7-tetrahydro-1H-indol-2-yl)aniline
英文别名
4-(1-Benzyl-4,5,6,7-tetrahydroindol-2-yl)aniline;4-(1-benzyl-4,5,6,7-tetrahydroindol-2-yl)aniline
4-(1-benzyl-4,5,6,7-tetrahydro-1H-indol-2-yl)aniline化学式
CAS
1450893-00-1
化学式
C21H22N2
mdl
——
分子量
302.419
InChiKey
HOFDOPBUOJYTMQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    23
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    31
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为产物:
    描述:
    6-乙炔基-7-氧杂双环[4.1.0]庚烷copper(l) iodide 、 lithium perchlorate 、 二乙胺三苯基膦 、 bis(dibenzylideneacetone)-palladium(0) 作用下, 以 乙腈 为溶剂, 反应 8.0h, 生成 4-(1-benzyl-4,5,6,7-tetrahydro-1H-indol-2-yl)aniline
    参考文献:
    名称:
    Pri病毒复制和Pri病毒突变蛋白毒性的小分子抑制剂。
    摘要:
    折叠:Pri病毒疾病是神经退行性疾病,其特征是细胞病毒蛋白(PrPC)的自我复制,错误折叠的同工型(PrPSc)在大脑中积累。没有针对这些病理的疗法。我们利用先前描述的基于细胞的分析方法来筛选小分子文库,并鉴定出55种能够抵消病毒复制和毒性的化合物。化合物55可以代表开发病毒疾病的全新疗法的起点。
    DOI:
    10.1002/cmdc.201700302
点击查看最新优质反应信息

文献信息

  • Synthesis of 4,5,6,7-Tetrahydro-1<i>H</i>-indole Derivatives Through Successive Sonogashira Coupling/Pd-Mediated 5-<i>endo</i>-<i>dig</i>Cyclization
    作者:Ivan A. Andreev、Dmitry S. Belov、Alexander V. Kurkin、Marina A. Yurovskaya
    DOI:10.1002/ejoc.201201417
    日期:2013.2
    A one-pot Sonogashira cross-coupling/5-endo-dig cyclization procedure leading to 2-aryl-4,5,6,7-tetrahydroindoles was developed. This short (only two steps from commercially available compounds) sequence avoids harsh conditions and expensive catalysts. Our procedure is highly tolerant to a range of functional groups (amino, nitro, carboxy, cyano, hydroxy, and bromo). A family of 21 tetrahydroindoles
    开发了导致 2-芳基-4,5,6,7-四氢吲哚的一锅 Sonogashira 交叉偶联/5-endo-dig 环化程序。这种短(仅从市售化合物中提取两个步骤)序列避免了苛刻的条件和昂贵的催化剂。我们的程序对一系列官能团(氨基、硝基、羧基、氰基、羟基和溴)具有高度耐受性。以克级规模合成了 21 种四氢吲哚家族,产率良好至极好,这表明该反应的一般特征和可扩展性。这种方法允许在 C2 位置(通过 ArI 的变化)和氮原子(通过 RNH2 的变化,包括手性部分)获得带有杂项取代基的吲哚。
  • Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold
    作者:Ivan A. Andreev、Dinesh Manvar、Maria Letizia Barreca、Dmitry S. Belov、Amartya Basu、Noreena L. Sweeney、Nina K. Ratmanova、Evgeny R. Lukyanenko、Giuseppe Manfroni、Violetta Cecchetti、David N. Frick、Andrea Altieri、Neerja Kaushik-Basu、Alexander V. Kurkin
    DOI:10.1016/j.ejmech.2015.04.022
    日期:2015.5
    Although all-oral direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) treatment is now a reality, today's HCV drugs are expensive, and more affordable drugs are still urgently needed. In this work, we report the identification of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole chemical scaffold that inhibits cellular replication of HCV genotype 1b and 2a subgenomic replicons. The anti-HCV genotype lb and 2a profiling and effects on cell viability of a selected representative set of derivatives as well as their chemical synthesis are described herein. The most potent compound 39 displayed EC50 values of 7.9 and 2.6 mu M in genotype lb and 2a, respectively. Biochemical assays showed that derivative 39 had no effect on HCV NS5B polymerase, NS3 helicase, IRES mediated translation and selected host factors. Thus, future work will involve both the chemical optimization and target identification of 2-phenyl-4,5,6,7-Tetrahydro-1H-indoles as new anti-HCV agents. (C) 2015 Elsevier Masson SAS. All rights reserved.
  • A Small-Molecule Inhibitor of Prion Replication and Mutant Prion Protein Toxicity
    作者:Tania Massignan、Valeria Sangiovanni、Silvia Biggi、Claudia Stincardini、Saioa R. Elezgarai、Giulia Maietta、Ivan A. Andreev、Nina K. Ratmanova、Dmitry S. Belov、Evgeny R. Lukyanenko、Grigory M. Belov、Maria Letizia Barreca、Andrea Altieri、Alexander V. Kurkin、Emiliano Biasini
    DOI:10.1002/cmdc.201700302
    日期:2017.8.22
    Into the fold: Prion diseases are neurodegenerative disorders characterized by the accumulation in the brain of a self-replicating, misfolded isoform (PrPSc ) of the cellular prion protein (PrPC ). No therapies are available for these pathologies. We capitalized on previously described cell-based assays to screen a library of small molecules, and identified 55, a compound capable of counteracting both
    折叠:Pri病毒疾病是神经退行性疾病,其特征是细胞病毒蛋白(PrPC)的自我复制,错误折叠的同工型(PrPSc)在大脑中积累。没有针对这些病理的疗法。我们利用先前描述的基于细胞的分析方法来筛选小分子文库,并鉴定出55种能够抵消病毒复制和毒性的化合物。化合物55可以代表开发病毒疾病的全新疗法的起点。
查看更多